Papaverine HCl Injection, USP, 60 mg/2 mL (30 mg/mL), packaged in a) 2mL Single-Dose Vial (NDC 0517-4002-01), and b) 25x2mL Single-Dose Vials (NDC 0517-4002-25), Rx Only, AMERICAN REGENT, INC., SHIRLEY, NY 11967.
Published August 26, 2026 · Recall initiated: July 24, 2026
Summary
FDA records drug Class I recall D-0800-2026, published August 26, 2026 and initiated July 24, 2026. Recalling firm: American Regent, Inc.; Status: Ongoing; Reported quantity: 86,100 vials; Lot: Lot #: 25202, Exp. Date: 11/30/2026. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde
What to do
Voluntary: Firm initiated · Press Release
Get an email if PAPAVERINE HYDROCHLORIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- PAPAVERINE HYDROCHLORIDE
- Manufacturer
- American Regent, Inc.
- Distributor
- Nationwide within the U.S
- UPC
- 0305174002257
- Lot
- Lot #: 25202, Exp. Date: 11/30/2026.
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMultrys (Trace Elements Injection 4, USP), For intravenous infusion, packaged in a) 1 mL Single-Dose Vial (NDCAugust 26, 2026
- FDATralement (trace elements injection 4*, USP), packaged in a) 1mL Single Dose vials (NDC 0517-9305-01) and b)August 26, 2026
- FDASelenious Acid Injection, USP 12 mcg/2 mL (6 mcg/2mL), For intravenous use, packaged in a) 2mL Single-DoseAugust 26, 2026
- FDAniCARdipine Hydrochloride Injection, USP, 25 mg/10mL (2.5 mg/mL), packaged in a) 10 mL Single Dose Vial (NDCAugust 26, 2026
- FDAACETYLCYSTEINE SOLUTION, USP, 20% (200 mg/mL), packaged in a) 4 mL Vial NOT FOR INJECTION (NDC 0517-7604-01),August 26, 2026
- FDAPAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials perApril 13, 2022
Questions about this recall
Was Papaverine HCl Injection, USP, 60 mg/2 mL (30 mg/mL), packaged in a) 2mL Single-Dose Vial (NDC 0517-4002-01), and b) 25x2mL Single-Dose Vials (NDC 0517-4002-25), Rx Only, AMERICAN REGENT, INC., SHIRLEY, NY 11967. recalled?
Yes. FDA published recall D-0800-2026 on August 26, 2026. Reported hazard: Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde
What should I do if I have this product?
Voluntary: Firm initiated · Press Release
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: PAPAVERINE HYDROCHLORIDE. UPC: 0305174002257.